

# oncoReveal® Essential LBx

## USER MANUAL



## Revision History

Version 1.0	Initial release
Version 2.0	<p>Updates to suppliers and catalog numbers in section 4</p> <p>Corrections to protocol workflow time required</p> <p>Clarifications to section 7.1 Gene-Specific PCR Purification</p> <p>Updates to MiSeq loading recommendations</p> <p>Minor formatting changes</p>
Version 3.0	<p>Added information about sequencing oncoReveal® Essential LBx libraries with oncoReveal® Fusion LBx libraries to sections 2 and 8</p> <p>Added DNA input quantities for tissue or FFPE sample types to section 6</p> <p>Added GS-PCR program for tissue or FFPE library preparation to section 7.1</p> <p>Updated amplicon number and Recommended Coverage in Table 1 to reflect pool update</p> <p>Added tissue- or FFPE-specific recommendations to Table 1</p> <p>Added MiSeq i100 flow cells and tissue multiplexing recommendations to Table 2.</p> <p>Including MiSeq i100 sequencing instructions callout in section 8</p> <p>Added negative control selection and analysis limitations for tissue or FFPE sample types to section 9.2</p> <p>Added PiVAT® instructions for 24.x and higher in section 9.3</p> <p>Minor grammatical changes and edits to improve clarity</p>
Version 4.0	<p>Included panel gene list in section 1</p> <p>Added section 12 Appendix B. ESR1 Limit of Detection (LOD) Study</p>

# Table of Contents

<b>1.</b>	<b>PRODUCT INTRODUCTION .....</b>	<b>3</b>
<b>2.</b>	<b>PRODUCT DESCRIPTION .....</b>	<b>3</b>
<b>3.</b>	<b>GUIDELINES .....</b>	<b>5</b>
3.1	cfDNA Sample Preparation and QC Guidelines .....	5
3.2	General Laboratory Guidelines .....	6
<b>4.</b>	<b>REAGENTS &amp; EQUIPMENT .....</b>	<b>7</b>
4.1	Kit Components .....	7
4.2	Liquid Biopsy (LBx) Unique Dual Indexing Kits .....	7
4.3	User-Supplied Reagents .....	7
4.4	Equipment .....	8
<b>5.</b>	<b>WORKFLOW .....</b>	<b>9</b>
<b>6.</b>	<b>DNA INPUT INFORMATION .....</b>	<b>10</b>
<b>7.</b>	<b>LIBRARY PREPARATION PROTOCOL .....</b>	<b>10</b>
7.1	Gene-Specific Target Amplification (GS-PCR) and Target Amplicon Purification .....	10
7.2	Index PCR and Purification .....	15
7.3	Quantitation and Normalization of Purified Libraries .....	18
<b>8.</b>	<b>SEQUENCING .....</b>	<b>20</b>
<b>9.</b>	<b>NEGATIVE CONTROL REQUIREMENTS AND VARIANT CALLING WITH PiVAT® ..</b>	<b>25</b>
9.1	Choosing a Negative Control Sample .....	25
9.2	Analysis of Tissue Samples using PiVAT® .....	26
9.3	Starting Your PiVAT® Run (PiVAT® version 24.x and higher) .....	27
9.4	Starting Your PiVAT® Run (PiVAT® version 23.x) .....	32
<b>10.</b>	<b>TROUBLESHOOTING LIBRARY PREPARATION .....</b>	<b>37</b>
<b>11.</b>	<b>APPENDIX A: INDEX SEQUENCES .....</b>	<b>41</b>
<b>12.</b>	<b>APPENDIX B. ESR1 LIMIT OF DETECTION (LOD) STUDY .....</b>	<b>45</b>

## 1. Product Introduction

The **oncoReveal® Essential LBx Panel** is a robust NGS assay that interrogates hundreds of somatic variants across 34 genes of interest from multiple solid tumor cancer types. The panel can detect four types of variants from cell-free DNA (cfDNA) that have been extracted from plasma: single nucleotide variants (SNVs), small insertion/deletion (indel) variants, copy number amplification (CNA), and microsatellite instability (MSI). For more information on the panel specifications, see the oncoReveal® Essential LBx product sheet (*Doc. No. MK-0050*).

**Table 1. List of genes included in the oncoReveal® Essential LBx Panel. TP53 has full CDS coverage; the remaining genes have hotspot coverage. Genes highlighted in blue can also detect Copy Number Amplifications (CNAs).**

AKT1	CTNNB1	FGFR2	KIT	PPP2R1A	SF3B1
ALK	EGFR	FGFR3	KRAS	PTCH1	SMAD4
AR	ERBB2	GNA11	MET	PTEN	TERT (promoter)
ATM	ERBB3	GNAQ	NRAS	RAC1	TP53
BRAF	ESR1	GNAS	PDGFRA	RET	
CDK4	FGFR1	HRAS	PIK3CA	RNF43	

The panel is designed to differentiate between variant signals that originate from tumor cells and healthy normal cells. This requires the use of cfDNA negative control samples. The detection of low-frequency variants and CNAs is achieved by modeling and by accounting for the noise and amplification profile of the negative controls. The choice of negative control samples and how they are run can impact the results. For more information refer to section 9: *Negative Control Requirements and Variant Calling with PiVAT®*.

Additionally, available as a complementary assay the **oncoReveal® Fusion LBx Panel** (*Part No.: HLA-HS-1005-24*) is designed to detect fusion transcripts from cell-free RNA (cfRNA) extracted from plasma. The oncoReveal® Essential LBx Panel, in conjunction with the oncoReveal® Fusion LBx Panel, contains numerous gene regions of interest that allow for the detection of somatic mutations (cfDNA) at very low frequencies as well as the detection of key fusions (cfRNA). For more information on the panel specifications see the oncoReveal® Essential LBx product sheet (*Doc. No.: MK-0050*) and the oncoReveal® Fusion LBx product sheet (*Doc. No.: MK-0049*).

## 2. Product Description

The oncoReveal® Essential LBx Panel utilizes our SLIMamp® (stem-loop inhibition-mediated amplification) technology allowing researchers to amplify regions of interest in a simple, single-tube multiplex PCR reaction. Pairs of DNA oligos designed for each region of interest, or hotspot, are used in the first round of gene-specific PCR (GS-PCR), and the products are subsequently purified via size selection. After purification a second round of PCR adds unique dual barcode index adaptors for sample tracking and sequencing. The oncoReveal® Essential LBx Panel contains sufficient reagents to prepare 24 libraries. Use of this panel requires a unique dual barcode indexing kit (available separately; see section 4.2) and the resulting libraries are designed for sequencing on the Illumina platform using a paired-end read length of at least 2 × 121 bp. The workflow of this panel can be performed and loaded onto the sequencing instrument within one day, and the protocol contains numerous stopping points for users who have time limitations.

**As the average amplicon size is 90 bp, sequencing greater than 121 bp may lead to lower read quality scores. However, sequencing using read lengths longer than 121 bp does not affect downstream data analysis performed using PiVAT®, Pillar Biosciences' proprietary secondary analysis pipeline.**

To identify SNV/indel variants down to 0.1% frequency with maximum sensitivity and specificity, we recommend starting with a cell-free DNA (cfDNA) input greater than or equal to 20 ng. Input DNA below 10 ng will amplify but with decreased sensitivity of variant detection.

**Before beginning library preparation, it is essential to review sections 8 and 9 that describe the loading schemes and the selection of negative control samples, respectively.** Note that SNV/indel and CNA controls can be used as in-lot controls for subsequent runs within the same kit lots.

The workflow of this panel can be processed in parallel with the oncoReveal® Fusion LBx Panel workflow once cDNA synthesis is completed, allowing interrogation of both cfDNA and cfRNA derived from cfTNA extracted from a single sample. The libraries can be loaded onto the sequencing instrument within one day, and the protocols contain numerous stopping points for users who have time limitations.



The oncoReveal® Essential LBx Panel is designed for sequencing and analysis of cfDNA. Tissue-based sequencing and analysis can be performed using this panel, however there are limitations as to its performance. For more information on tissue-specific recommendations, see sections 3.1, 6, 7.1, and 9.2.

### 3. Guidelines

#### 3.1 cfDNA Sample Preparation and QC Guidelines

- **Blood collection:** This panel was developed using Streck Cell-Free DNA BCT® tubes (*Cat. No. 230469, 230470, 230471*). Plasma should be isolated according to the manufacturer's guidelines. Plasma can be isolated up to 7 days after blood draw when the tubes are stored between 18°C to 25°C. Streck Cell-Free DNA BCT tubes have a capacity of 10 mL, and isolation of plasma from a full blood draw will typically produce between 4 mL and 5 mL. However, yields may vary due to differences between individual donors. Performance characteristics of other collection tube types, such as K<sub>2</sub>EDTA, have not been evaluated with this assay.
- **cfDNA extraction:** The oncoReveal® Essential LBx Panel was developed and extensively tested the Qiagen QIAamp Circulating Nucleic Acid Kit (*Cat. No. 55114*) to extract cfDNA. Other extraction methods may be used however their performance has not been assessed and results may vary.
- **Input volume:** The QIAamp Circulating Nucleic Acid Kit is compatible with sample volumes from 1 mL to 5 mL. To increase cfDNA yield, extraction from either 4 mL or 5 mL of plasma is recommended.
- **Elution volume:** The elution volume of the QIAamp Circulating Nucleic Acid Kit is 20 µL to 150 µL. An elution volume of 30 µL is recommended to increase cfDNA concentration.
- **Cross-contamination:** The oncoReveal® Essential LBx Panel is extremely sensitive, allowing for the detection of variants down to 0.1% allele frequencies. As such, it is crucial that care be taken during all steps of sample preparation to avoid inaccuracies in downstream results arising from pre-analytical errors. Consult section 3.2 for more details.
- **Quantification:** Quantification using the Invitrogen Qubit dsDNA High Sensitivity Assay kit (*Thermo Fisher Scientific, Cat. No. Q32851, Q32854*) is recommended for cfDNA extracted using the QIAamp Circulating Nucleic Acid Kit. The Qubit dsDNA High Sensitivity Assay kit is highly selective for double-stranded DNA. Due to the presence of carrier RNA in the eluate, quantification with spectrophotometry or with fluorometric methods that utilize single-stranded binding dyes may cause overestimation of cfDNA quantity.
- **Genomic DNA (gDNA) contamination:** gDNA contamination is caused by the lysis of white blood cells in either the blood or the plasma sample. The presence of gDNA contamination in cfDNA extracts may cause underestimation of variants or false negative results, especially for variants present at low allele frequencies. The manufacturer's guidelines for sample collection and processing should be followed carefully to minimize contamination. Additionally, several QC methods are recommended to check for gDNA contamination
  - *Gel Electrophoresis:* Typical cfDNA samples will contain fragments between 50 bp and 700 bp in size, with one major band occurring around 150 bp and a second major band around 300 bp. Observation of bands or smearing above 700 bp indicates the presence of gDNA contamination.
  - *TapeStation:* Sample QC with Agilent Cell-free DNA ScreenTape (*Cat. No. 5067-5630*) provides a measurement of %cfDNA. Lower %cfDNA values indicate the presence of contaminating gDNA.
  - *qPCR:* A qPCR method utilizing amplicons of varying fragment sizes may be used for both cfDNA quantification as well as assessment of gDNA contamination. This method is particularly useful if alternative cfDNA extraction kits are used.

- **cfDNA input:** To identify SNV/indel variants down to 0.1% frequency with maximum sensitivity and specificity, we recommend starting with a cell-free DNA input greater than or equal to 20 ng, with a target of at least 5 million clusters (~10 million paired-end reads). Input DNA below 10 ng will amplify but with decreased sensitivity of variant detection.
- **gDNA input:** If using FFPE or tissue sample, to identify SNV/indel variants down to 1% frequency, it is recommended to start with DNA input of at least 20ng, with a sequencing target of 1.5 million clusters (~3 million paired-end reads).

### 3.2 General Laboratory Guidelines

The following steps are recommended to improve consistency and reduce contamination:

- **Work areas:** To reduce the risk of contamination from PCR amplicons, supplies should not be moved from one area to another. Separate storage areas (refrigerator, freezer) should also be designated for pre- and post-PCR products.
- **Lab cleanliness:** To further reduce the possibility of contamination, work areas should be cleaned between experiments with laboratory cleaning solution (70% alcohol or freshly-made 10% hypochlorite solution). A periodic cleaning of the floor is also recommended.
- **Floor:** Items that have fallen to the floor are assumed to be contaminated and should be discarded. If a sample tube or non-consumable item has fallen to the floor and remained sealed, the outer surface of the item should be thoroughly cleaned before use with 70% alcohol or freshly-made 10% hypochlorite solution. Gloves should be changed after handling a contaminated item.
- **Aliquot reagents:** Frozen reagents should be aliquoted into smaller volumes to reduce freeze/thaw cycles. To reduce the risk of stock contamination it is recommended to aliquot from the stock and work from the aliquots. In case of contamination, the use of aliquots can also help to determine the source more quickly and easily.
- **Multichannel pipettes:** Multichannel pipettes should be used to maintain consistency and efficiency across numerous samples.
- **Pipette tips:** Tips should be changed between each sample to prevent cross-contamination. Any tips that may have become contaminated due to contact with gloves, the lab bench, tube exteriors, etc., should be discarded.
- **Open containers and lids:** To prevent possible contamination from the air, tubes should be kept closed when not directly in use, and plates, troughs, and similar reservoirs should be covered with seals or lint-free laboratory wipes. Additionally, reaching over open containers should be avoided.

## 4. Reagents & Equipment

This section describes the necessary equipment, reagents, and consumables needed before performing the protocol.

All reagents should be used in designated pre-PCR or post-PCR areas to prevent amplicon contamination. Each area designated for pre- and post-PCR should have dedicated equipment, reagents, and supplies (including gloves, lab coats, etc.) to prevent contamination.

### 4.1 Kit Components

oncoReveal® Essential LBx Panel Part No.: HLA-HS-1006-24

Reagent	Use	Area Use	Storage
PCR HiFi 4x Master Mix	Gene-Specific PCR and Indexing PCR	Pre-PCR	-25°C to -15°C
oncoReveal® Essential LBx Oligo Pool	Gene-Specific PCR	Pre-PCR	-25°C to -15°C
GC Rescue G	Gene-Specific PCR	Pre-PCR	-25°C to -15°C
Magnesium chloride	Gene-Specific PCR	Pre-PCR	-25°C to -15°C

### 4.2 Liquid Biopsy (LBx) Unique Dual Indexing Kits

Reagent	Part Number	Use	Area Use	Storage
Pillar Biosciences LBx Indexing Kit A (24 combinations, 96 reactions)	IDX-PI-1013-96	Indexing PCR	Pre-PCR	-25°C to -15°C
Pillar Biosciences LBx Indexing Kit B (24 combinations, 96 reactions)	IDX-PI-1014-96	Indexing PCR	Pre-PCR	-25°C to -15°C

*Only one index kit is needed per assay. Multiple options are available to meet various throughput needs. Kits A and B can be combined for a total of 48 unique dual index combinations.*

### 4.3 User-Supplied Reagents

Reagent	Area Use	Supplier
Negative control cfDNA	Pre-PCR	Refer to section 9 of this manual
10N NaOH or 1N NaOH	Post-PCR	General lab supplier
AMPure XP Beads	Post-PCR	Beckman Coulter, Cat# A63881 or A63880
Ethanol, 200 proof for molecular biology	Post-PCR	General lab supplier
Nuclease-free water	Post-PCR	General lab supplier
Qubit dsDNA High Sensitivity Assay kit	Post-PCR	Invitrogen, Cat# Q32851 or Q32854
Agarose gel, 2% (optional) <sup>1</sup>	Post-PCR	General lab supplier
DNA molecular weight markers (optional) <sup>1</sup>	Post-PCR	General lab supplier
10 mM Tris-HCl w/ 0.1% Tween-20, pH 8.5 (optional)	Post-PCR	Teknova, Cat# T7724
PhiX Control v3	Post-PCR	Illumina, Cat# FC-110-3001
200 mM Tris-HCl, pH 7.0	Post-PCR	General lab supplier

<sup>1</sup> *The Qubit dsDNA High Sensitivity Assay kit is the primary DNA quantitation assay used throughout this protocol. Additional DNA quantification can optionally be performed using an agarose gel or using the TapeStation DNA Analysis kit.*



## Compatible Sequencing Reagents

Sequencing Reagent Kit	Supplier	Catalog No.
MiSeq™ Reagent kit v3 (600 cycles) ‡	Illumina	MS-102-3003
NextSeq™ 500/550 Mid Output v2.5 kit (300 cycles) ‡	Illumina	20024905
NextSeq™ 500/550 High Output v2.5 kit (300 cycles)	Illumina	20024908
NextSeq™ 1000, NextSeq™ 2000, NovaSeq™ 6000	Illumina	Refer to Illumina's website

‡ Indicates the flow cells the oncoReveal® Essential LBx Panel has been validated on. However, libraries generated using this protocol are compatible with all Illumina sequencers.

## General Laboratory Consumables

In addition to the consumables listed below, other general laboratory supplies needed to carry out the protocol include gloves, ice buckets, tube racks, etc.

Consumable	Area Use	Supplier
1.5 mL microcentrifuge tubes	Pre- and Post-PCR	General lab supplier
96-well PCR plates, 0.2 mL	Pre- and Post-PCR	Fisher Scientific, Cat# 14-222-334 or equivalent
Microplate sealing film	Pre- and Post-PCR	Fisher Scientific, Cat# 14-222-347 or equivalent
Conical tubes, 15 mL	Pre- and Post-PCR	General lab supplier
Conical tubes, 50 mL	Post-PCR	General lab supplier
Low retention, aerosol filter pipette tips	Pre- and Post-PCR	General lab supplier
Solution basin (trough or reservoir)	Pre- and Post-PCR	Fisher Scientific, Cat# 13-681-506 or equivalent
Qubit Assay tubes	Post-PCR	Invitrogen, Cat# Q32856

## 4.4 Equipment

Equipment	Area Use	Supplier
Centrifuge adapted for PCR plates, tabletop	Pre- and Post-PCR	General lab supplier
Gel electrophoresis apparatus (optional)*	Post-PCR	General lab supplier
TapeStation or equivalent	Post-PCR	Agilent Technologies
Magnetic stand for 96 wells	Post-PCR	Life Technologies, Cat# 12331D or 12027
Microfuge	Pre- and Post-PCR	General lab supplier
Thermal cycler, heated lid capability	Post-PCR	General lab supplier
Pipettes, 0.5-1000 µL capabilities	Pre- and Post-PCR	General lab supplier
Qubit Fluorometer	Post-PCR	Invitrogen, Cat# Q33216/Q33218
Vortex mixer	Pre- and Post-PCR	General lab supplier

\* The Qubit dsDNA High Sensitivity kit is the primary DNA quantitation assay used throughout this protocol. Additional DNA quantification can optionally be performed using an agarose gel.

## 5. Workflow

The following chart demonstrates the workflow for performing the **oncoReveal® Essential LBx Panel** library preparation.







Figure 1. Library preparation workflow for **oncoReveal® Essential LBx Panel**. The workflow can be completed within a day but contains multiple optional stopping points for users with time constraints.

Symbol	Description
	<b>Information:</b> Information that follows this symbol is important and may require action.
	<b>Optional Stopping Point:</b> A point in the workflow at which work may be safely paused and samples can be stored appropriately.
	<b>Caution:</b> Information that follows this symbol is critical to the workflow. Information following this symbol should not be skipped or ignored.

*Symbols used throughout this protocol and their associated meaning.*

## 6. DNA Input Information

The following protocol provides information for preparing libraries using cfDNA isolated from plasma. See section 3.1 for details on cfDNA sample preparation and quantification.

**Recommended DNA input per sample: 10 – 30 ng cfDNA**

If using tissue or FFPE DNA, recommended DNA input per sample:

- Genomic DNA (from tissue, cell lines): minimum 20 ng
- FFPE DNA: minimum 20 ng. If FFPE DNA is severely degraded, increase the input when possible.

## 7. Library Preparation Protocol

<b>Hands-on Time</b>	3 – 5 hours
<b>Total Time</b>	6.75 – 8.5 hours

### 7.1 Gene-Specific Target Amplification (GS-PCR) and Target Amplicon Purification

<b>Hands-on Time</b>	30 – 45 min.
<b>Total Time</b>	2.25 – 2.5 hours

#### Amplify cfDNA Targets

The following steps should be performed in a pre-PCR area.

For this portion of the protocol prepare a pre-chilled cooler and keep the PCR HiFi 4x Master Mix, the custom oligo pool, and GC Rescue G in the cooler until needed.

1. **Prepare Gene-Specific PCR Mix 1 (GS-PCR Mix 1):** Vortex and centrifuge the PCR HiFi 4x Master Mix and the oligo pool before use. For each PCR reaction, the volume of each component is listed below.



**Important:** The gene-specific PCR master mix reagent is viscous. Ensure the mix is fully homogenized before adding other reaction components. Vortexing is recommended and will not adversely affect enzyme activity.

GS-PCR Mix 1	
Reagent	Volume (μL)
PCR HiFi 4x Master Mix	12.5
Essential LBx Oligo Pool	1.0
GC Rescue G	2.5
Magnesium chloride	1.0
<b>Subtotal</b>	<b>17.0</b>

- Transfer:** Transfer **17 μL** of GS-PCR Mix 1 to each sample well in a PCR plate, strip tube, or PCR tube.
- Dilute input DNA:** Add **33 μL** of DNA\* (diluted if necessary) to each sample well containing GS-PCR Mix 1. Add **33 μL** of nuclease-free water to the no-template control well.



When performing an in-batch normal run, cfDNA (≥20 ng) from a healthy individual is recommended as input, for a target of at least **20M paired-end reads** (i.e., the in-batch normal should generate twice as many reads as a sample). Note that this will reduce the test sample capacity of the flow cell by 2. Please see sections 8 and 9 for further information.

Final GS-PCR Mix	
Reagent	Volume (μL)
GS-PCR Mix 1	17.0
DNA (or water)	33.0
<b>Total</b>	<b>50.0</b>

\* The DNA concentration can be determined using the Qubit dsDNA HS Assay Kit

- Seal and mix:** Carefully seal the reactions and vortex for 10 – 15 seconds.
- Spin:** Briefly centrifuge the reactions to remove any air bubbles from the bottom of the wells and to spin down droplets from the seal or side walls.

The following steps should be performed in a post-PCR area.

- Perform GS-PCR:** Perform the following program with the heated lid on for cfDNA:

GS-PCR Program (cfDNA)		
Temperature	Time	Number of Cycles
95°C	15 sec	1
95°C	1 min	10
58°C	2 min	
60°C	4 min	
64°C	1 min	
72°C	1 min	
8°C	Hold	1

If using tissue or FFPE DNA, perform the following program with the heated lid on:

GS-PCR Program (gDNA)		
Temperature	Time	Number of Cycles
95°C	15 sec	1
97°C	1 min	10
58°C	2 min	
60°C	4 min	
64°C	1 min	
72°C	1 min	
8°C	Hold	1



Do not leave reactions on the thermocycler overnight at 8°C. Once cycling is complete the reactions can be stored at -20°C.



**Optional Stopping Point:** The gene-specific PCR reactions may be stored at -20°C after cycling is complete.

### Purify the Gene-Specific PCR Product

<b>Hands-on Time</b>	60 – 90 min.
<b>Total Time</b>	60 – 90 min.

The following steps should be performed in a post-PCR area.

*Before beginning the purification:*

- Remove the AMPure XP beads from 4°C and incubate at room temperature for at least 30 minutes before use.



**Caution:** Ensure that the AMPure bead solution reaches room temperature before performing the purification. The temperature of the bead solution can have adverse effects on the purification process.

- If gene-specific PCR products were stored at -20°C, allow them to thaw at room temperature and then proceed immediately to purification.
- Prepare 70% ethanol by mixing three parts of water with seven parts of absolute ethanol in a conical tube, invert the tube a few times to mix, and dispense sufficient volume into a disposable trough for convenient dispensing when using a multichannel pipette.



**Caution:** Fresh 70% ethanol is required for optimal results.

### Gene-Specific Product Purification

1. If condensation has formed or if the reactions were stored at -20°C briefly centrifuge the reactions upon thawing. Carefully remove the seal.

2. **Mix Beads:** Vortex AMPure XP beads thoroughly until all beads are well-dispersed.



**Caution:** Ensure that the AMPure bead solution is homogenous. A non-uniform distribution can have unpredictable effects on the purification process.

3. **Add beads:** Add 75 µL of AMPure beads (equivalent to a 1.5x bead ratio) to each well. Pipette the mixture up and down 10 times. If bubbles form on the bottom of the wells, briefly centrifuge the PCR plate and mix again.

4. **Bind GS-PCR product to beads:** Incubate for 5 minutes at room temperature.

5. **Separate beads containing GS-PCR product:** Place the PCR plate on a magnetic rack until the solution appears clear, which can take up to 5 minutes.

6. **Remove supernatant:** Carefully remove the supernatant from each well without disturbing the beads.

7. **Resuspend beads:** Remove the PCR plate from the magnetic rack and resuspend the beads in each well using 53 µL of nuclease-free water. Gently pipette the suspension up and down 10 times. If bubbles form on the bottom of the wells briefly centrifuge and mix again.

8. **Incubate:** Incubate for 5 minutes at room temperature.

9. **Separate GS-PCR product from beads:** Place the PCR plate on a magnetic rack at room temperature until the solution appears clear. Transfer 50 µL of clear supernatant from each well of the PCR plate to a new PCR plate.

10. **Add beads:** With the eluted product from step 9, add 75 µL of AMPure beads (equivalent to a 1.5x bead ratio) to each well. Pipette the mixture up and down 10 times. If bubbles form on the bottom of the wells briefly centrifuge the samples and mix again.

11. **Bind GS-PCR product to beads:** Incubate for 5 minutes at room temperature.

12. **Separate beads containing GS-PCR product:** Place the PCR plate on a magnetic rack until the solution appears clear, which can take up to 5 minutes.

13. **Remove supernatant:** Carefully remove the supernatant from each well without disturbing the beads

14. **Wash beads:** With the PCR plate still on the magnetic rack add 150 µL of freshly prepared 70% ethanol to each well without disturbing the beads. Incubate at room temperature for 30 seconds and then remove the supernatant from each well.



**Important:** Do not allow the ethanol mixture to remain open to the air. The ethanol concentration will change over time, affecting the washing of the beads. Pour only enough solution for each wash.

15. **Second wash:** Repeat step 14 for a second 70% ethanol wash.

16. **Remove remaining ethanol wash:** Centrifuge for 10–15 seconds, place the PCR plate back on the magnetic rack, and use a 10 µL or 20 µL tip to remove the remaining ethanol solution at the bottom of the wells.

17. **Dry beads:** Keep the PCR plate on the magnetic rack and let the beads air dry at room temperature for 2–5 minutes.



**Important:** To mitigate product loss, do not allow the beads to over-dry. The beads have sufficiently dried when the bead mass has small cracks in the middle. If large cracks have appeared among the entire bead ring or they are flaky, they are over-dried. Beads that are too dry may be difficult to resuspend.

18. **Resuspend Beads:** Remove the PCR plate from the magnetic rack and resuspend the dried beads in each well using 32 µL of nuclease-free water. Gently pipette the suspension up and down 10 times. If bubbles form on the bottom of the wells, briefly centrifuge and mix again.

*TIP: After resuspending the beads, cover the reactions and prepare for the indexing PCR step using the PCR HiFi 4x Master Mix. The PCR HiFi 4x Master Mix should be handled in the pre-PCR area. Alternatively, the purified gene-specific PCR product may be stored at -20°C after elution.*

19. **Incubate and Elute:** Incubate for 5 minutes at room temperature.
20. **Separate GS-PCR product from beads:** Place the PCR plate on a magnetic rack at room temperature until the solution appears clear. Transfer 30 µL of clear supernatant from each well of the PCR plate to a new PCR plate.



**Optional Stopping Point:** The purified GS-PCR products can be stored at -20°C.

## 7.2 Index PCR and Purification

### Indexing PCR: Amplify the Libraries

<b>Hands-on Time</b>	20 – 40 min.
<b>Total Time</b>	80 – 100 min.



**Important:** Save time by preparing the indexing PCR plate during Gene-Specific PCR.

The following steps should be performed in a pre-PCR area.

For this portion of the protocol prepare a pre-chilled cooler. The PCR HiFi 4x Master Mix should be kept in the cooler until it is needed.

1. **Prepare Indexing PCR Mix 1:** Briefly vortex and centrifuge the PCR HiFi 4x Master Mix before use. To prepare Indexing PCR Mix 1, combine HiFi Master Mix and water with sufficient overage.

Indexing PCR Mix 1 (per reaction)	
Reagent	Volume (μL)
PCR HiFi 4x Master Mix	12.5
Nuclease-free water	23.5
<b>Subtotal</b>	<b>36.0</b>

2. Transfer **36 μL** of the Indexing PCR Mix 1 to each sample well of a new PCR plate.
3. **Add Indexing Primers:** Transfer **8 μL** of unique, pre-mixed Index Mix P5xx & P7xx to each sample well of the PCR plate containing Indexing PCR Mix 1. Ensure no well-to-well cross-contamination during indexing primer transfer.

Indexing PCR Mix 2 (per reaction)	
Reagent	Volume (μL)
Indexing PCR Mix 1	36.0
Index Mix P5xx & P7xx	8.0
<b>Subtotal</b>	<b>44.0</b>

The following steps should be performed in a post-PCR area. Cover or seal the reactions before transferring from the pre-PCR area to the post-PCR area.

If the GS-PCR products were stored at -20°C after purification, ensure that the samples have been completely thawed at room temperature before proceeding.

4. **Add purified GS-PCR product:** Add **6 μL** of purified GS-PCR product into the appropriate wells containing Indexing PCR Mix 2.



Indexing PCR Final Mix (per reaction)	
Reagent	Volume (µL)
Indexing PCR Mix 2	44.0
Purified Gene-Specific PCR product	6.0
<b>Total</b>	<b>50.0</b>

5. **Seal and mix:** Carefully seal the reactions and vortex for 10–15 seconds.
6. **Spin:** Briefly centrifuge the reactions to remove any air bubbles from the bottom of the wells and to spin down droplets from the seal or side walls.
7. **Perform Indexing PCR:** Perform the following program with the heated lid on.

Indexing PCR Program		
Temperature	Time	Number of Cycles
95°C	2 min	1
95°C	30 sec	18*
66°C	30 sec	
72°C	1 min	
72°C	5 min	1
8°C	Hold	1

*Additional Indexing PCR cycles can be performed if the final library yield is low or if initial DNA input is below recommended minimum.*



**Optional Stopping Point:** The indexed libraries can be stored at -20°C after cycling is complete.

### Indexing PCR: Purify the Libraries

<b>Hands-on Time</b>	30 – 45 min.
<b>Total Time</b>	30 – 45 min.

#### *Before beginning the purification:*

- Keep AMPure XP beads at room temperature while the Indexing PCR is being performed unless samples will be stored at -20°C after the program is complete.
- If the indexed libraries were stored at -20°C, remove them from the freezer to thaw thoroughly to ambient temperature before purification. After samples have thawed, briefly centrifuge to remove any droplets from the side walls. Remove AMPure XP beads from 4°C and incubate at room temperature for at least 30 minutes before use.



**Caution:** Ensure that the AMPure bead solution reaches room temperature before performing the purification. The temperature of the bead solution can have adverse effects on the purification process.

## Library Purification

The following steps should be performed in a post-PCR area.

1. **Mix beads:** Vortex AMPure XP beads thoroughly until all beads are well dispersed.



**Caution:** Ensure that the AMPure bead solution is homogenous. A non-uniform distribution can have unpredictable effects on the purification process.

2. **Add beads:** Add 60  $\mu\text{L}$  beads (equivalent to a 1.2x bead ratio) to each well. Pipette the mixture up and down 10 times. If bubbles form on the bottom of the wells, briefly centrifuge and mix again.

3. **Bind libraries to beads:** Incubate for 5 minutes at room temperature.

4. **Separate libraries on beads:** Place the PCR plate on a magnetic rack until the solution appears clear, which can take up to 5 minutes.

5. **Remove supernatant:** Carefully remove the supernatant from each well without disturbing the beads.

6. **Wash beads:** With the PCR plate still on the magnetic rack add 150  $\mu\text{L}$  of freshly prepared 70% ethanol to each well without disturbing the beads. Incubate at room temperature for 30 seconds and then remove the supernatant from each well.



**Caution:** Do not allow the ethanol mixture to remain open to the air. The ethanol concentration will change over time, affecting the washing of the beads. Pour only enough solution for each wash.

7. **Second wash:** Repeat step 6 for a second 70% ethanol wash.

8. **Remove remaining ethanol wash:** Centrifuge the PCR plate for 10–15 seconds, place it back on the magnetic rack, and use a 10  $\mu\text{L}$  or 20  $\mu\text{L}$  tip to remove any trace amounts of ethanol from each well.

9. **Dry beads:** Let the beads air dry at room temperature for 2–5 minutes.



**Important:** To mitigate product loss, do not allow the beads to over-dry. The beads have sufficiently dried when the bead mass has small cracks in the middle. If large cracks have appeared among the entire bead ring or they are flaky, they are over-dried. Beads that are too dry may be difficult to resuspend.

10. **Resuspend beads:** Remove the PCR plate from the magnetic rack and resuspend the dried beads in each well using 32  $\mu\text{L}$  of nuclease-free water. Gently pipette the bead suspension up and down 10 times. If bubbles form on the bottom of the wells briefly centrifuge and mix again.

11. **Elute libraries:** Incubate at room temperature for 5 minutes.

12. **Separate libraries from beads:** Place the bead suspensions on the magnetic rack at room temperature until the solution appears clear. Transfer 30  $\mu\text{L}$  of clear supernatant from each well of the PCR plate to a new plate.

*TIP: During the incubation and magnetic separation of the beads, cover the samples with microplate sealing film and prepare the solutions needed for quantitation performed in the next section.*

13. **Quantification:** Analyze an aliquot of each library per the instructions in the next section.



**Optional Stopping Point:** The purified libraries can be stored at 4°C for up to 3 days, or at -20°C for longer-term storage.

### 7.3 Quantitation and Normalization of Purified Libraries

Prior to sequencing libraries must be quantified, normalized, and then pooled together. The following section describes how to quantify libraries using the Qubit system. Other library quantification methods, such as qPCR quantification kits or Bioanalyzer, may be used according to the manufacturer's protocol.

#### Qubit Quantitation

<b>Hands-on Time</b>	30 – 45 min.
<b>Total Time</b>	30 – 45 min.

The following steps should be performed in a post-PCR area.

1. **Prepare Qubit working solution:** Dilute the Qubit dsDNA HS reagent 1:200 in Qubit dsDNA HS buffer. Vortex briefly to mix the Qubit working solution.

*For example, 2000 µL is sufficient buffer for 10 readings (8 samples + 2 standards). Combine 1990 µL of Qubit dsDNA HS buffer and 10 µL HS reagent. Add reagent overage appropriately.*



**Important:** Fluorescent dyes are sensitive to light. Protect the Qubit working solution from light.

2. **Label tubes:** Set up 0.5 mL Qubit tubes for standards and samples. Label the tube lids.
3. **Prepare standards:** Transfer **190 µL** of Qubit working solution into two tubes for standard 1 and standard 2 and then add **10 µL** of each standard to the corresponding tube.



**Caution:** New standard dilutions should be prepared with the libraries to be quantified. Do not re-use standard dilutions from previous experiments.

4. **Prepare samples:** Transfer **198 µL** of Qubit working solution to each 0.5 mL tube and then add **2 µL** of each library to its corresponding Qubit tube (1:100 dilution).
5. **Mix and spin:** Vortex to mix and then centrifuge the tubes briefly.
6. Incubate the tubes at room temperature for 2 minutes.

7. **Measure concentration:** Measure the concentration of each library on the Qubit Fluorometer per the manufacturer's instructions. Use the dsDNA High Sensitivity assay to read standards 1 and 2 followed by the libraries.

If any concentration is above the linear range of the instrument, prepare a new dilution by combining 199 µL Qubit working solution and 1 µL library (1:200 dilution). Repeat steps 5–7.

8. **Calculate concentration:** 1 ng/µL of library is equal to 6 nM. An example calculation is below. Adjust the dilution factor accordingly.

2 µL of library + 198 µL Qubit working solution:

$$\frac{\text{Qubit reading } \left(\frac{\text{ng}}{\text{mL}}\right)}{1,000} \times \text{dilution factor (100)} \times \text{conversion factor (6)} = \text{nM}$$



**Optional Stopping Point:** Once libraries have been quantified either proceed with normalization and pooling or else keep them stored at 4°C for up to 3 days. Store libraries at -20°C for long-term storage.

## Normalization and Pooling

<b>Hands-on Time</b>	30 – 45 min.
<b>Total Time</b>	30 – 45 min.

The following steps should be performed in a post-PCR area.

1. **Normalize libraries to 5 nM:** Dilute an aliquot (e.g., 4 µL) of each sample library to 5 nM using nuclease-free water or 10 mM Tris-HCl with 0.1% Tween-20, pH 8.5. For NTCs, use the same dilution scheme as the library with the lowest measured concentration. An example calculation is as follows:

$$\frac{\text{Library concentration (nM)} \times 4 \mu\text{L library}}{5 \text{ nM}} = \text{final volume of library}$$

$$\text{Final volume of library} - 4 \mu\text{L library} = \text{volume of diluent}$$

2. **Mix and spin:** Mix the 5 nM libraries thoroughly by vortexing and then centrifuge briefly.
3. **Prepare library pool:** Label a new 1.5 mL microtube for the library pool. Prepare an equimolar 5 nM mixture of libraries by combining each library at equal volume (e.g., mixing 5 µL of each 5 nM library). Gently pipette the entire solution up and down 10 times to mix thoroughly. Quickly vortex the pool and then briefly centrifuge.



**Caution:** If the in-batch normal sample library was included, mix **2x** volume of the in-batch normal library with the other libraries (e.g., 10 µL of in-batch normal library and 5 µL of each 5 nM library). The in-batch normal should generate twice as many reads as a sample.

4. **Quantify library pool (recommended):** It is recommended that the library pool be quantified using Qubit or another library quantitation method (qPCR) to ensure the pool is at 5 nM (± 10%) to prevent poor sequencing performance. If the final dilution is not 5 nM (± 10%), adjust the dilution for loading the sequencer accordingly to obtain the desired concentration.



**Optional Stopping Point:** The normalized libraries can be stored at 4°C overnight for sequencing the next day. For longer storage, the normalized libraries can be stored at -20°C.

## 8. Sequencing

### Prepare Diluted Libraries for Sequencing

<b>Hands-on Time</b>	30 – 40 min.
<b>Total Time</b>	30 – 40 min.

The libraries generated using this protocol can be multiplexed and sequenced on Illumina® sequencers. Table 2 outlines the sequencing parameters and the recommended per-sample sequencing coverage. The number of samples that can be multiplexed together is dependent on several factors, among which are the estimated throughput of the flow cell and sequencing platform, the desired sequencing depth, as well as the number of unique index combinations available.

To identify SNV/indel variants down to 0.1% frequency with maximum sensitivity and specificity, we recommend starting with cfDNA input greater than or equal to 20 ng with a target of least 5 million clusters (equivalent to ~10 million paired-end reads). Input DNA below 10 ng will amplify but with decreased sensitivity of variant detection.

If sequencing oncoReveal® Essential LBx libraries with oncoReveal® Fusion LBx libraries, see oncoReveal® Fusion LBx Panel User Manual (Doc. No.: UM-0078), section 7 for multiplexing recommendations and additional sequencing information.

The estimated **maximum** number of samples that can be multiplexed on a single flow cell using each kit is displayed in Table 3. Select the appropriate sequencing kit based on the number of samples to be sequenced. An example of the loading scheme is shown in Table 4. The recommended reads per sample and the estimated instrument output reported in Table 2 and Table 3, respectively, are equivalent to the number of sequencing clusters multiplied by 2.

$$\text{Recommended reads per sample} = \left( \frac{\text{Number of amplicons} \times \text{Recommended Coverage}}{\text{On - Target Rate as a decimal}} \right) \times 2$$

$$\text{Estimated Maximum Sequencing Batch Size} = \frac{\text{Estimated Instrument Output}}{\text{Recommended reads per sample}}$$

Table 2. Sequencing recommendations.

Input type	Sequencing Configuration	Index	Recommended Coverage	Recommended Reads Per Sample
cfDNA	2 × 121	Unique dual indices (8 bp each)	Mean: 21,000X	~10 million PE reads
gDNA (Tissue or FFPE)	2 × 121	Unique dual indices (8 bp each)	Mean: 6,000X	~3 million PE reads

Table 3. Multiplexing recommendations for Illumina sequencers.

Sequencing Flow Cell	Estimated Instrument Output (Million PE Reads)	Estimated Maximum Sequencing Batch Size		
		cfDNA: In-batch control used	cfDNA: Out-of-batch control used	Tissue: No polishing control required
MiSeq v3	50	3	5	16
MiSeq i100 25M	50	3	5	16
MiSeq i100 50M	100	8	10	33
MiSeq i100 100M	200	18	20	66
NextSeq 500/550 Mid Output	260	24	26	86

Calculations assume ≥85% effective on-target rate after read mapping and minimum segment coverage >20% of the mean coverage. Multiplexing numbers reflect the number of samples that can be pooled together on a flow cell if in-batch controls are used or if out-of-batch controls are used.



When performing an in-batch normal run, cfDNA ( $\geq 20$  ng) from a healthy individual is recommended as input, for a target of at least **-20M paired-end reads** (i.e., the in-batch normal should generate twice as many reads as a sample). Note that this will reduce the test sample capacity in the flow cell by half.

**Table 4. Loading scheme examples using either an in-batch control or an out-of-batch control.**

In-batch control run			Out-of-batch control run	
MiSeq v3	NextSeq Mid	Library pooling volume	MiSeq v3	NextSeq Mid
Negative control	Negative control	8 $\mu$ L	N/A	N/A
NTC (optional)	NTC (optional)	4 $\mu$ L	NTC (optional)	NTC (optional)
Sample1	Sample1	4 $\mu$ L	Sample1	Sample1
Sample2	Sample2	4 $\mu$ L	Sample2	Sample2
Sample3	Sample3	4 $\mu$ L	Sample3	Sample3
	Sample4	4 $\mu$ L	Sample4	Sample4
	Sample5	4 $\mu$ L	Sample5	Sample5
	Sample6	4 $\mu$ L		Sample6
	Sample7	4 $\mu$ L		Sample7
	Sample8	4 $\mu$ L		Sample8
	Sample9	4 $\mu$ L		Sample9
	Sample10	4 $\mu$ L		Sample10
	Sample11	4 $\mu$ L		Sample11
	Sample12	4 $\mu$ L		Sample12
	Sample13	4 $\mu$ L		Sample13
	Sample14	4 $\mu$ L		Sample14
	Sample15	4 $\mu$ L		Sample15
	Sample16	4 $\mu$ L		Sample16
	Sample17	4 $\mu$ L		Sample17
	Sample18	4 $\mu$ L		Sample18
	Sample19	4 $\mu$ L		Sample19
	Sample20	4 $\mu$ L		Sample20
	Sample21	4 $\mu$ L		Sample21
	Sample22	4 $\mu$ L		Sample22
	Sample23	4 $\mu$ L		Sample23
	Sample24	4 $\mu$ L		Sample24
		4 $\mu$ L		Sample25
		4 $\mu$ L		Sample26

The following steps should be performed in a post-PCR area.

For this portion of the protocol have a pre-chilled benchtop cooler prepared.

### Sequencing Using Illumina's MiSeq™ Reagents

**MiSeq recommended final library pool loading concentration: 15 pM**

**MiSeq recommended PhiX spike-in concentration: 15 pM**

The following steps can be found in greater detail in Illumina's "MiSeq System: Denature & Dilute Libraries Guide" (Doc# 15039740).

1. **Normalize:** Dilute libraries to 5 nM, as demonstrated in section 7.3 "Normalization and Pooling".
2. **Prepare 0.2 N NaOH:** Label a new 1.5 mL microtube for 0.2 N NaOH. Prepare the NaOH by combining **800 µL** of nuclease-free water with **200 µL** of 1 N NaOH. Vortex the solution to mix.  
  
*NOTE: Alternatively, prepare a 1 N NaOH solution by combining 500 µL of 10 N NaOH with 4.5 mL of nuclease-free water. Vortex the solution to mix. If 1 N NaOH has not been prepared within the last week from a 10 N solution, prepare a new 1 N NaOH solution.*
3. **Denature the library pool:** Label a new 1.5 mL microtube for the denatured 25 pM library pool.
  - a. Denature the 5 nM library pool by combining **5 µL** of the library pool and **5 µL** of the freshly prepared 0.2 N NaOH.
  - b. Vortex thoroughly for 10 seconds and centrifuge for 1 minute.
  - c. Let the solution stand at room temperature for 5 minutes.
  - d. Add **990 µL** of Illumina's HT1 hybridization buffer to the denatured library pool.
  - e. Invert the mixture several times, centrifuge briefly, and place it in the cooler.
4. **Dilute 25 pM library mix to 15 pM:** Label a new 1.5 mL microtube for the 12.5 pM library mix. Combine **360 µL** of the 25 pM library pool with **240 µL** of Illumina's HT1 hybridization buffer. Adjust the volumes as needed for libraries that are over or under 25 pM. Invert the mixture several times, centrifuge briefly, and place it in the cooler.
5. **Combine library mix and PhiX control:** Label a new 1.5 mL microtube for the mixture that will be loaded onto the sequencer. Combine **594 µL** of the 15 pM library pool with **6 µL** of 15 pM PhiX library control. Briefly vortex, centrifuge, and place in the cooler.
6. **Load MiSeq cartridge:** Using a clean 1000 µL tip puncture the foil cap above the sample loading well on the MiSeq cartridge. Load the **600 µL** library pool and PhiX mixture into the reagent cartridge, ensuring that the solution has reached the bottom of the well.
7. **Run the MiSeq:** Sequence the libraries on the MiSeq per the manufacturer's instructions using a paired-end read length of 121 (2 × 121) and two indexing reads of 8 cycles each. See "MiSeq System User Guide" (part #15027617).
8. **Store** diluted libraries and mixtures at -20°C for long-term storage.

## Sequencing Using Illumina's NextSeq™ 500/550 Reagents

**Recommended final library pool loading concentration: 1.5 pM**

**Recommended PhiX spike-in concentration: 1.5 pM**

1. **Normalize:** Dilute libraries to 5 nM, as demonstrated in section 7.3 “Normalization and Pooling”.
2. **Prepare 0.2 N NaOH:** Label a new 1.5 mL microtube for 0.2 N NaOH. Prepare the NaOH by combining **800 µL** nuclease-free water with **200 µL** of 1 N NaOH. Vortex the solution to mix.  
  
*NOTE: Alternatively, prepare a 1 N NaOH solution by combining 500 µL of 10 N NaOH with 4.5 mL of nuclease-free water. Vortex the solution to mix. If 1 N NaOH has not been prepared within the last week from a 10 N solution, prepare a new 1 N NaOH solution.*
3. **Denature the library pool:** Label a new 1.5 mL microtube for the denatured 25 pM library pool.
  - a. Denature the 5 nM library pool by combining **5 µL** of the library pool and **5 µL** of the freshly prepared 0.2 N NaOH.
  - b. Vortex thoroughly for 10 seconds and centrifuge for 1 minute.
  - c. Let the solution stand at room temperature for 5 minutes.
  - d. Add **5 µL** of 200 mM Tris-HCl, pH 7.0.
  - e. Vortex briefly and centrifuge for 1 minute.
  - f. Add **985 µL** of Illumina's HT1 hybridization buffer to the denatured library mix.
  - g. Vortex briefly and centrifuge for 1 minute.
4. **Dilute 25 pM library mix to 1.5 pM:** Dilute the denatured library to 1.5 pM in 1400 µL by combining **84 µL** of the 25 pM denatured library mix with **1316 µL** of Illumina's HT1 hybridization buffer. Invert to mix and centrifuge briefly.
5. **Combine library mix and PhiX control:** Label a new 1.5 mL microtube for the mixture that will be loaded. Combine **1287 µL** of the 1.5 pM library mix with **13 µL** of a 1.5 pM PhiX library control. Briefly vortex, centrifuge, and place in the cooler.
6. **Load NextSeq cartridge:** Using a clean 1000 µL tip, puncture the foil cap above the sample loading well on the NextSeq cartridge. Load **1300 µL** library and PhiX mixture into the cartridge and ensure the solution has reached the bottom of the cartridge well.
7. **Run the NextSeq:** Sequence the libraries on the NextSeq per the manufacturer's instructions using a paired-end read length of 121 (2 × 121) and two indexing reads of 8 cycles each. See “NextSeq System User Guide” (part #15046563 or #15069765).
8. **Store** diluted libraries and mixtures at -20°C for long-term storage.

## Sequencing Using Illumina's MiSeq 1000 Reagents

**Recommended final library pool loading concentration: 50 pM**

For sequencing instructions, see Illumina's “MiSeq 1000 Plus System Product Documentation: Protocol” (Doc# 200055785).



## Preparing a Sample Sheet for Sequencing

**TIP:** Prepare the sample sheet prior to loading the sequencing reagent cartridge. If an error has been made during the indexing PCR where samples have the same indices, it can be remedied before loading the samples on the sequencer.

The available Pillar indexing primers and their barcode sequences are listed in Appendix A. The Pillar sample sheet generator will automatically populate the correct barcode sequence when the indexing primer is selected.

In the Pillar sample sheet generator, prepare a sample sheet that contains the information for the samples that are being loaded. Ensure that the appropriate sample sheet is being made for the sequencing instrument used.

1. Open the Pillar sample sheet generator and enter user input in the shaded cells. Cells that are shaded blue are required and cells that are shaded grey are optional.
2. Enter the "Sample\_ID" for each sample. Each Sample\_ID must be unique and contain only alphanumeric characters, dashes (-), and underscores (\_). No other characters are allowed. To check that the Sample\_ID meets all requirements click "Reset Sample\_ID color" and then click "Check Sample\_ID".
3. If text is green, the Sample\_ID is acceptable. If text is red, Sample\_ID is not acceptable. Change Sample\_ID accordingly and repeat step 2 until all text is green.
4. Next, enter indices into appropriate fields. Index sequences will be populated once the index\_ID is entered.
5. Library preparation using the oncoReveal® Essential LBx Panel requires the use of unique dual barcodes. Using Pillar Bioscience's LBx Indexing Kit A and LBx Indexing Kit B a maximum of 48 index combinations are available. If sequencing more than 48 libraries, do not load samples together in the same run that have the same index combination.
6. Once all requirements for the sample sheet are met, export the sample sheet as a comma-separated values (.csv) file by clicking "Export".
7. The recommended read length for oncoReveal® Essential LBx libraries is at least 2×121 bp. Open the .csv file and input the read length that will be used during the sequencing run.

## 9. Negative Control Requirements and Variant Calling with PiVAT®

The oncoReveal® Essential LBx Panel identifies four types of variants: single nucleotide variants (SNVs), small insertion/deletion (indels) variants, copy number amplification (CNA), and microsatellite instability (MSI). The panel is designed to facilitate downstream analysis in PiVAT®, differentiating between variant signals originating from tumor cells and healthy normal cells. PiVAT® does so by utilizing both a negative control sample and control regions in the panel. PiVAT® uses sequencing data from the negative control to model and remove noise. The choice of negative control and how those control samples are loaded impacts your results.

### 9.1 Choosing a Negative Control Sample

A negative control sample is any healthy individual cfDNA or contrived cfDNA sample that is free of somatic variants, including CNA. FFPE tissue samples are not suitable to serve as a negative control, as the process of formalin fixation introduces DNA damage.

Young healthy individual cfDNA samples are the best choice for the negative control as they are the closest match possible to a subject's cfDNA. While healthy individual cfDNA is recommended to be used as the negative control, contrived normal cfDNA samples may also be used. The performance difference compared to healthy individual cfDNA is negligible for SNV/indel calling, but significant for CNA calling. If a negative control is not provided, SNV and indel variant calls will still be generated, but with lower specificity, and CNA calls will not be generated. For improved CNA calling, three (3) healthy individual cfDNA negative control samples are recommended. CNA calling improves slightly with additional negative controls, up to 5 as capacity will allow.

**Recommendation:** At least 20 ng of cfDNA from a healthy individual, sequenced with a target of at least 20 million paired-end reads. If no healthy individual samples are available, contrived samples may be used as a replacement. Internal testing has shown that Anchor Molecular Normal cfDNA (*Part No. MS-0293*) allows for good SNV and indel calling, but relatively poor CNA calling (see table of recommendations below).

#### Including negative control samples in your run

Negative controls can be generated and sequenced with each run (in-batch control) or generated once per reagent lot and used repeatedly for analysis (out-of-batch control). If both options are viable, in-batch controls are recommended.



When performing an in-batch normal run, cfDNA (≥20 ng) from a healthy individual is recommended as input, for a target of at least **20 M paired-end reads** (i.e., the in-batch normal should generate twice as many reads as a sample). Note that this will reduce the test sample capacity in the flow cell by 2. See sections 7 and 9 for further information.

**Recommendation:** Healthy individual cfDNA run in a single batch and used as an out-of-batch negative control for future runs within the same reagent lot.

#### Can MSI matched normal samples be used as negative controls?

PiVAT® provides users with the ability to initiate MSI analysis using either a matched normal or unmatched mode. While using a matched normal sample, such as a buffy coat provides the highest sensitivity results for MSI calling, these matched samples cannot be used as negative controls for SNV/indel or CNA calling as they fail to capture the profile of cfDNA; only healthy or contrived cfDNA samples are suitable as a negative control.

Note that not all versions of PiVAT® support the unmatched normal mode for MSI calling. Contact your account executive to confirm if your PiVAT® version can process your sample using the unmatched normal mode.

## Recommended negative controls

	Recommended	Acceptable	Poor
SNV/Indel only	Healthy cfDNA (1)	Contrived cfDNA (1)	
CNA only	Healthy cfDNA (3)	Healthy cfDNA (1)	Contrived cfDNA (1)
SNV/Indel + CNA	Healthy cfDNA (3)	Healthy cfDNA (1)	Contrived cfDNA (1)



PiVAT® version 2023.x and before does not perform both matched normal MSI calling and SNV/indel or CNA calling in the same run. If profiling of both types of variants is desired, the same run must be queued twice: once with matched MSI calling only and once with SNV/indel and CNA calling.

As of PiVAT® 24.2, a single run can support unmatched normal MSI calling, SNV/indel, and CNA calling.

## 9.2 Analysis of Tissue Samples using PiVAT®

For the analysis of tissue samples instead of cfDNA, it is recommended that the target sequencing be at least 1.5M clusters, 3M paired-end reads per sample.

There is no negative control requirement for SNV/indel calling. The lowest VAF achieved is 1% with this sample type.

PiVAT® requires negative controls for CNA calling when analyzing tissue samples (see table above for number of negative control samples). CNA calling sensitivity is reduced, with a minimum gain restricted to 1.5 copy-number ratio. Negatives controls do not need to be sequenced at an additional depth for CNA calling. Out-of-batch negative controls will provide worse performance than using in-batch negative controls.




**Caution:** There is limited support for CNA calling when analyzing tissue samples with the oncoReveal® Essential LBx Panel. If the negative control condition or handling differs from the samples', the CNA algorithm will capture the biases instead of the true calls.


## 9.3 Starting Your PiVAT® Run (PiVAT® version 24.x and higher)

You can specify your normal samples in PiVAT® using the following steps:


1. Click on “Start Analysis” to start your new run




2. Navigate to the directory that contains your FASTQ files




3. Ensure that the directory you selected populates the green box in the bottom right corner and then click Next.




4. If the standard Illumina naming convention was used with the file naming, PIVAT® will be able to parse and group the files appropriately.



- Select **oncoReveal Essential LBx (p-lbx-04)** from the panel dropdown.



- Click on “Set Panel” to set oncoReveal Essential LBx as the panel for all the samples.



- Verify that the correct panel was selected for all the samples.

**Create New PiVAT Analysis**

1. Start From 2. Configure 3. Analysis Configuration 4. Preview & Launch

Panel: The PiVAT panel to use for this analysis.

oncoReveal Essential LBx Panel ( p-lbx-04 ) [Set Panel] [Edit Sample]

Sample Name	Panel	Sample Files
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-AM-D6-10ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-AM-D6-30ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-NTC-D6-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-SCCv2-D6-AF-Op5-10ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-SCCv2-D6-AF-Op5-30ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-SCCv2-D6-AF-Op25-30ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]
<input checked="" type="checkbox"/> RDvSMpFocus231101IN4-SCCv2-D6-AF-Op125-30ng-rep1	oncoReveal Essential LBx Panel ( p-lbx-04 )	(8) [icon]

[Back] [Next]

- Specify your “Run Name”, and from the sample listing table, select the sample you want to use as “Polishing Normal Sample”. If you also want to perform CNA analysis, please also select a copy neutral sample as the “CNV Normal Sample”. Note: in this example, the same sample (Anchor Molecular gDNA normal) is being used as the polishing and CNV normal sample.

**Create New PiVAT Analysis**

1. Start From 2. Configure 3. Analysis Configuration 4. Preview & Launch

Panel: oncoReveal Essential LBx Panel ( p-lbx-04 ) Pipeline: 2024.2.3 Parameter: [dropdown]

Run Name: demo\_run

Sample Name	QC Type	CNV Normal	Polishing Normal	Tumor Content %
RDvSMpFocus231101IN4-AM-D6-10ng-rep1	Sample	#Select_#	#Select_#	#Input_#
RDvSMpFocus231101IN4-AM-D6-30ng-rep1	Sample	CNV Normal Sample	Polishing Normal Sample	#Input_#
RDvSMpFocus231101IN4-NTC-D6-rep1	Sample	#Select_#	#Select_#	#Input_#
RDvSMpFocus231101IN4-SCCv2-D6-AF-Op5-10ng-rep1	Sample			
RDvSMpFocus231101IN4-SCCv2-D6-AF-Op5-30ng-rep1	Sample			
RDvSMpFocus231101IN4-SCCv2-D6-AF-Op25-30ng-rep1	Sample			
RDvSMpFocus231101IN4-SCCv2-D6-AF-Op125-30ng-rep1	Sample			

[Back] [Next]

9. Finally, verify the run configuration and click on “Launch Analysis”

**Create New PIVAT Analysis**

1. Start From 2. Configure Samples For Analysis 3. Analysis Configuration 4. Preview & Launch

Email Address: your@email.com

Panel: oncoReveal Essential LBx Panel Pipeline: 2024.2.3 Parameter: Run name: demo\_run

Sample Name *	QC Type	CNV Normal	Polishing Normal	Tumor Content %
RDvSMpFocusd231101IN4-AM-D6-10ng-rep1	Sample	--	--	--
RDvSMpFocusd231101IN4-AM-D6-30ng-rep1	Sample	CNV Normal Sample	Polishing Normal Sample	--
RDvSMpFocusd231101IN4-NTC-D6-rep1	Sample	--	--	--
RDvSMpFocusd231101IN4-SCCv2-D6-AF-Qp5-10ng-rep1	Sample	--	--	--
RDvSMpFocusd231101IN4-SCCv2-D6-AF-Qp5-30ng-rep1	Sample	--	--	--
RDvSMpFocusd231101IN4-SCCv2-D6-AF-Qp25-30ng-rep1	Sample	--	--	--
RDvSMpFocusd231101IN4-SCCv2-D6-AF-Qp125-30ng-rep1	Sample	--	--	--


Back Launch Analysis




## 9.4 Starting Your PiVAT® Run (PiVAT® version 23.x)

You can specify your negative control samples in PiVAT® using the following steps:

1. Set up your analysis run by selecting the correct panel type and FASTQ input. The negative control FASTQ files should be selected as well.



2. For SNV/indel, specify your negative control sample by selecting “NegCtrl” from the drop down under the “QC Type” column.



- For CNA calling, select your sample first, then click on the “Define CNV Normal Samples” button above the sample table.

2. Then click on “Define CNV Normal Samples”

1. If you want to specify a copy number neutral sample, select the sample you want to use as copy number neutral sample

3. For accurate sample level CN calculation, specify the tumor content for the samples. If tumor content is not supplied, PiVAT will try to estimate from observed variant frequencies.

Note that the term “Normal Sample” is identical to “Negative Control” sample. For performing both SNV/indel and CNA calling, the same sample can be used as negative control. This will move your sample to the bottom of the table under “Normal Samples”:

Normal Samples


RDvSMpCoreAd230515IN3-AM-20ng-rep1

NegCtrl

Undefine All


- If matched normal MSI calling run is needed, perform the set up in the following manner.

*Matched normal MSI calling and CNA calling are mutually exclusive calling modes. PiVAT® will only run in one of the two calling modes in a single run.*




Note that not all versions of PiVAT® support the unmatched normal mode for MSI calling. Contact your account executive to confirm if your PiVAT® version can process your sample using the unmatched normal mode.


- Enter a name for the matched pair.




Once the name has been selected, it will move your sample to the bottom of the table under “Tumor-Normal Paired SAMPLE\_NAME”:



6. Verify that the tumor and normal sample selections are accurate:



7. Verify the run set up in the last window. Remember to scroll all the way down and confirm that your negative control samples are reflected appropriately.



8. Once the run set up has been confirmed, launch the analysis.

## 10. Troubleshooting Library Preparation

### Low Yield of Gene-Specific Product

Potential Cause	Solution
<b>DNA quantity or quality</b>	The recommended input for the assay is 10–30 ng of cell free DNA. Higher quantities may be necessary for low- or poor-quality samples.
<b>Improper cycling</b>	Check that the cycling protocol performed is the appropriate protocol for gene-specific amplification.

### Low Indexing Efficiency

Potential Cause	Solution
<b>Improper AMPure purification</b>	Incomplete AMPure purification or loss of gene-specific product will affect the indexing PCR reaction. The purified gene-specific product can be checked on an agarose gel to ensure the product was not lost, and that the clean-up was sufficient to remove excess primers.
	The AMPure bead ratio and ethanol concentration affect the PCR clean-up. Ensure that the correct AMPure bead concentration was used for clean-up, and fresh 70% ethanol was used for the wash.
	Leftover ethanol from the wash steps can hinder the PCR reaction. Remove as much of the ethanol during the final wash step with a pipette and dry the beads to ensure the residual ethanol has evaporated.

### Low Yield of Final Library

Potential Cause	Solution
<b>DNA quantity or quality</b>	The recommended input for the assay is 10–30 ng of cell free DNA. Higher quantities may be necessary for low- or poor-quality samples.
	Run the product from the gene-specific PCR on an agarose gel to check the yield.
<b>Improper AMPure purification</b>	Incomplete AMPure purification or loss of product will affect the final yield. The purified product can be checked on an agarose gel to ensure that the product was not lost during PCR clean-up.
	The AMPure bead ratio and ethanol concentration affect the PCR clean-up. Ensure that the correct AMPure bead concentration was used for clean-up, and fresh 70% ethanol was used for the wash.


### Amplicon Contamination in No-Template Control

Potential Cause	Solution
<b>Cross-contamination</b>	Make sure to change tips between samples and avoid waving tips over tubes or plates.
	Poor sealing or residual liquid in tips can cause contamination of nearby samples. If possible, leave adjacent wells empty between samples.
	Workspaces and equipment for pre-PCR and post-PCR should be separated to prevent amplicon contamination.
	Periodically clean the workspace, floor, equipment, and instrumentation with a laboratory cleaning solution to break down amplicons on surfaces.
	Recommended cleaning solutions are 10% bleach, 70% isopropanol, or 70% ethanol.


### Sequencing Performance

Potential Cause	Solution
<b>Improper normalization and pooling of libraries</b>	Confirm that the appropriate loading concentration was used for the applicable sequencing instrument.
	Check the 5 nM library mix using Qubit or RT-PCR. Dilute the denatured library mix as needed to adjust for the difference in concentration.
<b>Improper library quantitation</b>	<p>Improper library quantitation may result in artificially high or low yields, which affects downstream normalization.</p> <p>Re-quantitate the final libraries and/or the normalized libraries to check for the expected values.</p>
<b>Improper AMPure purification</b>	<p>Changing the ratio of AMPure beads affects the purification of the products. Notably, the presence of primer dimers can cause an underestimation of total quantity, causing over-clustering.</p> <p>The final libraries can be checked on an agarose gel for the proper product size and presence of primer dimers.</p>
	The AMPure bead ratio and ethanol concentration affect the PCR clean-up. Ensure that the correct AMPure bead concentration was used for clean-up, and fresh 70% ethanol was used for the wash.

Few or No Somatic Variant Calls

Potential Cause	Solution
Low input sample	The oncoReveal® Essential LBx Panel is designed for input of at least 10 ng cfDNA. Samples below the recommended input range (10-30 ng) will have significantly lower sensitivity.
Low coverage or low input negative control	Check that the negative control was sequenced to at least 20 million paired-end reads and was at least 20 ng of cfDNA from a healthy individual.
Genomic DNA (gDNA) contamination	<p>gDNA contamination may cause underestimation of variants or false negative results, especially for variants present at low allele frequencies. Verify that the sample does not have high levels of gDNA contamination.</p> <div></div> <p>Example of cell-free DNA TapeStation analysis demonstrating <b>low gDNA contamination</b>.</p>





Example of cell-free DNA TapeStation analysis demonstrating **high gDNA contamination**.

## II. Appendix A: Index Sequences

i7 Index Sequences	
Index ID	Index Barcode Sequence for MiSeq and NextSeq Sample Sheet
Pi713	GAAACCCA
Pi714	TGTGACCA
Pi715	AGGGTCAA
Pi716	AGGAGTGG
Pi717	ACGTTACC
Pi718	CTGTGTTG
Pi719	TGAGGTGT
Pi720	GATCCATG
Pi721	GCCTATCA
Pi722	AACAACCG
Pi723	ACTCGTTG
Pi724	CCTATGGT
Pi725	TGTACACC
Pi726	GTATGCTG
Pi727	TGATGTCC
Pi728	GTCTTCT
Pi729	ATAAGGCG
Pi730	CTTACCTG
Pi731	CGTTGCAA
Pi732	GATTCAGC
Pi733	TCACGTTT
Pi734	TGTGCGTT
Pi735	TAGTTGCG
Pi736	ACAGCTCA
Pi737	GTTAAGGC
Pi738	AAGCCACA
Pi739	ACACGGTT
Pi740	CAGCGATT
Pi741	TAGTGACC
Pi742	CGAGACTA
Pi743	GACATGGT
Pi744	GCATGTCT
Pi745	ACTCCATC
Pi746	CGAAGAAC
Pi747	GGTGTCTT
Pi748	AAGAAGGC
Pi749	CATGTTCC
Pi750	GTGCCATA

i7 Index Sequences	
Index ID	Index Barcode Sequence for MiSeq and NextSeq Sample Sheet
Pi751	CCTTG TAG
Pi752	GCTGG ATT
Pi753	TAACG AGG
Pi754	ATGGT TGC
Pi755	CCTAT ACC
Pi756	TTAGG TCG
Pi757	GCAAG ATC
Pi758	AGAGC CTT
Pi759	GCAAT GGA
Pi760	CTGGAGTA

i5 Index Sequences		
Index ID	Index Barcode Sequence for MiSeq Sample Sheet	Index Barcode Sequence for NextSeq Sample Sheet
Pi513	CTAATCGA	TCGATTAG
Pi514	CTAGAACA	TGTTCTAG
Pi515	TAAGTTCC	GGAACCTA
Pi516	TAGACCTA	TAGGTCTA
Pi517	ACCGACAA	TTGTCGGT
Pi518	AGTGGCAA	TTGCCACT
Pi519	CACAGACT	AGTCTGTG
Pi520	CGACACTT	AAGTGTCTG
Pi521	GACTTGTTG	CACAAGTC
Pi522	GTGAGACT	AGTCTCAC
Pi523	GTTCCATG	CATGGAAC
Pi524	TAGCTGAG	CTCAGCTA
Pi525	CTTCGCAA	TTGCGAAG
Pi526	GTGGTATG	CATACCAC
Pi527	CACTGTAG	CTACAGTG
Pi528	AGACGCTA	TAGCGTCT
Pi529	CAACTCCA	TGGAGTTG
Pi530	AACACGCT	AGCGTGTT
Pi531	TGGATGGT	ACCATCCA
Pi532	TTCGAAGC	GCTTCGAA
Pi533	AACACCAC	GTGGTGTT
Pi534	TGAGCTGT	ACAGCTCA
Pi535	CACAGGAA	TTCCTGTG
Pi536	TGACAACC	GGTTGTCA
Pi537	CCTAGAGA	TCTCTAGG
Pi538	GCATAACG	CGTTATGC
Pi539	CAGTGCTT	AAGCACTG
Pi540	CGTATCTC	GAGATACG
Pi541	CGTCAAGA	TCTTGACG
Pi542	CCATGAAC	GTTTCATGG
Pi543	GGTACTTC	GAAGTACC
Pi544	ACCGCTAT	ATAGCGGT
Pi545	TTCCAGGT	ACCTGGAA
Pi546	TCGAACCT	AGGTTCTGA
Pi547	TAGTGCCA	TGGCACTA
Pi548	GGTACGAA	TTCGTACC
Pi549	AAGCATCG	CGATGCTT
Pi550	GCCAATAC	GTATTGGC
Pi551	CTGTATGC	GCATACAG
Pi552	CTTAGGAC	GTCCTAAG
Pi553	ACATGCCA	TGGCATGT
Pi554	GATGGAGT	ACTCCATC
Pi555	CGATCGAT	ATCGATCG
Pi556	TACTCCAG	CTGGAGTA

i5 Index Sequences		
Index ID	Index Barcode Sequence for MiSeq Sample Sheet	Index Barcode Sequence for NextSeq Sample Sheet
Pi557	AGCTACCA	TGGTAGCT
Pi558	TCGACAAG	CTTGTCGA
Pi559	TATGACCG	CGGTCATA
Pi560	AGCCAACT	AGTTGGCT

## 12. Appendix B. ESR1 Limit of Detection (LOD) Study

The performance of the oncoReveal® Essential LBx panel for ESR1 variant detection at low variant allele frequencies was assessed in the whitepaper *Pillar® oncoReveal® Essential LBx Panel: Investigating the panel performance for hotspot ESR1 variants* (Doc. No. MK-0062).

Standard reference samples and cfDNA from healthy donors were used in this study. The following molecular standards were used to assess DNA performance:

- Seraseq® ctDNA ESR1 Mutation Mix AF 1% (Cat# 0710-3565) consists of 22 clinically relevant mutations in ESR1 (n=18) and PIK3CA (n=4), each at approximately 1% variant allele frequency (VAF). The fragment size ranges from 155-200 bp.
- Seraseq® ctDNA ESR1 Mix WT (Cat# 0710-3564) is the corresponding wildtype sample that was used for dilution as well as the negative sample for specificity calculation.
- Anchor Molecular's AM Normal cfDNA (Cat# 60133001) sample was used for polishing control
- 23 cfDNA samples from 13 healthy donors were collected in-house. 10 mL of blood samples were collected in Streck Cell-Free DNA BCT tube. 4 mL plasma were isolated from each tube. QIAamp Circulating Nucleic Acid kit (Cat#55114) was used for extraction. The yields of cfDNA from 4 mL plasma range from 15 to 54 ng. The cfDNA input used for the Essential LBx assay varies from 5 ng to 30 ng.

A dilution series of the Seraseq® ctDNA ESR1 Mutation Mix AF 1% standard was generated to create samples with allele fractions of 0.50%, 0.20%, 0.10%, and 0.05%. Libraries of the original stock and the four dilutions were prepared as per the protocol in section 7 with DNA inputs of 5 ng, 10 ng, 20 ng, and 30 ng. DNA libraries were normalized and loaded on Illumina's NextSeq mid-output kit with 2 x 121 bp configuration according to section 8. Sequencing reads were processed on PiVAT 24.2.3 and the results were analyzed for performance estimation.

All expected variants were consistently called across replicates and DNA sample inputs in 1% stock standard sample as well as in the 0.5% dilutions (Table 5). As the sample concentration reduces, a higher Positive Percent Agreement (PPA) is observed with larger DNA inputs.

The limit of detection (LoD) for ≥10 ng of the panel is estimated to be in the 0.05%-0.1% range. The PPA (observed n/expected N) [95% confidence interval; CI] at 0.1% for ≥10 ng samples is 98.1% (106/108) [93.5%, 99.8%]. Whereas the PPA at 0.05% for 30 ng samples is 82.4% (89/108) [73.9%, 89.1%]. For the positions tested in this study, no false positive calls were observed in the healthy donor cfDNA samples, leading to a 100% Negative Percent Agreement (NPA) for these sites (Table 5). A detailed, per-site observed VAF (%) data for 30 ng input is provided in Table 6.

Table 5. Panel performance for positive and negative samples. Positive percent agreement (PPA) and negative percent agreement (NPA) for the oncoReveal® Essential LBx Panel for the Seraseq® ctDNA ESR1 Mutation Mix AF 1% serial dilutions and negative samples. The bold cells highlight the lowest inputs at which the best performance is observed for each dilution.

Positive Samples				
Sample Allele Fraction	Replicates	PPA (Observed n/Expected N) [95% CI]		
		10 ng	30 ng	
1.00% (Stock)	2	Not tested	100% (42/42) [91.6%, 100%]	
0.50%	3	100% (63/63) [94.3%, 100%]	100% (63/63) [94.3%, 100%]	
0.20%	3	100% (63/63) [94.3%, 100%]	100% (63/63) [94.3%, 100%]	
0.10%	3	95.2% (60/63) [86.9%, 98.4%]	98.4% (62/63) [91.5%, 99.7%]	
0.05%	3	66.7% (42/63) [54.4%, 77.1%]	81% (51/63) [69.6%, 88.8%]	
Negative Samples				
Sample Type	Samples	Negative Agreed	Negative Expected	NPA (n/N) [95% CI]
Healthy donor cfDNA	24	504	504	100.0% (504/504) [99.2%, 100.0%]

Table 6. Observed variant allele frequency (%) for each dilution's replicate at 30 ng sample input. Only one call is missed in the 0.10% replicates, whereas 12 variants are missing for 0.05% (shown in **bold red font**).

Gene	Genomic change	Amino acid change	1.00%		0.50%			0.20%			0.10%			0.05%			Negative Sample
			Rep 1	Rep 2	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3	
ESR1	c.1138G>C	E380Q	1.69	1.68	0.72	0.86	0.76	0.24	0.27	0.36	0.11	0.15	0.16	0.06	0.08	0.14	o
	c.1387T>C	S463P	1.48	1.24	0.49	0.63	0.8	0.25	0.15	0.21	0.12	0.14	0.19	0.07	<b>o</b>	0.12	o
	c.1603C>A	P535T	1.84	2.08	1.31	1.22	1.2	0.55	0.54	0.88	0.3	0.16	0.57	0.17	0.15	0.09	o
	c.1607_1608delinsAT	L536H	1.87	1.95	1.47	1.08	0.78	0.59	0.44	0.3	0.12	0.38	0.27	0.13	0.07	0.07	o
	c.1607T>A	L536H	1.92	1.78	0.91	0.9	1	0.65	0.44	0.58	0.13	0.16	0.17	0.15	0.14	0.26	o
	c.1607T>C	L536P	1.34	1.51	1.05	1.01	0.82	0.35	0.38	0.34	0.14	0.25	0.18	0.08	0.07	0.12	o
	c.1607T>G	L536R	1.83	1.82	0.97	1.3	1.01	0.42	0.47	0.39	0.37	0.2	0.21	0.13	0.1	0.06	o
	c.1607_1608delinsAG	L536Q	2.19	1.6	1.46	1.32	1.31	0.63	0.55	0.58	0.2	0.26	0.36	<b>o</b>	0.11	<b>o</b>	o
	c.1610_1611delinsCA	Y537S	1.74	1.68	1.1	1.01	0.96	0.45	0.52	0.59	0.21	0.28	0.15	0.08	0.14	0.24	o
	c.1609_1610delinsAG	Y537S	2.11	1.97	1.06	1.13	1.24	0.28	0.48	0.63	0.24	0.28	0.26	0.12	0.16	0.11	o
	c.1610A>C	Y537S	1.55	1.43	0.78	0.82	0.93	0.46	0.42	0.43	0.3	0.19	0.12	<b>o</b>	0.08	0.04	o
	c.1609T>A	Y537N	2.44	1.84	1.13	1.14	1.05	0.5	0.69	0.46	0.32	0.2	0.32	0.13	<b>o</b>	<b>o</b>	o
	c.1608_1609delinsTA	Y537N	1.84	2.07	0.78	1.48	1.23	0.67	0.52	0.39	0.33	0.18	0.13	<b>o</b>	0.16	0.17	o
	c.1610A>G	Y537C	1.8	1.47	1.46	1.04	0.76	0.6	0.65	0.43	0.45	0.25	0.07	0.1	0.17	0.16	o
	c.1609T>G	Y537D	2.1	1.53	0.9	1.39	1.17	0.37	0.38	0.72	0.29	0.12	0.1	0.11	0.26	<b>o</b>	o
	c.1613A>G	D538G	1.99	1.6	0.93	1.13	0.83	0.4	0.51	0.39	0.27	0.25	0.36	0.14	0.16	0.08	o
	c.1610_1615dup	D538_L539insHD	1.85	2.11	0.95	1.12	0.93	0.38	0.36	0.62	0.14	0.2	0.15	0.06	0.03	0.12	o
	c.1625A>G	E542G	1.01	0.98	0.61	0.63	0.52	0.4	0.27	0.25	0.08	0.11	0.15	0.07	0.07	0.06	o
PIK3CA	c.1624G>A	E542K	0.82	1.03	0.53	0.46	0.41	0.16	0.11	0.26	0.13	0.15	0.06	<b>o</b>	<b>o</b>	0.11	o
	c.1633G>A	E545K	1.13	1.38	0.46	0.45	0.55	0.19	0.16	0.19	0.13	<b>o</b>	0.1	0.07	0.07	0.09	o
	c.3140A>G	H1047R	1.03	1.02	0.44	0.6	0.41	0.16	0.38	0.16	0.21	0.08	0.12	<b>o</b>	0.05	<b>o</b>	o